Elisabeth Wehrle

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford et al. · Blood · 2010 · 481 citations · Full text

Imatinib Plasma Levels Are Correlated With Clinical Benefit in Patients With Unresectable/Metastatic Gastrointestinal Stromal Tumors

George D. Demetri, Yanfeng Wang, Elisabeth Wehrle et al. · Journal of Clinical Oncology · 2009 · 396 citations · Full text

Surgical Oncology, Pathology, Pharmacotherapy +16

Follow-up results after 9 years (yrs) of the ongoing, phase II B2222 trial of imatinib mesylate (IM) in patients (pts) with metastatic or unresectable KIT+ gastrointestinal stromal tumors (GIST).

Margaret von Mehren, Michael C. Heinrich, Heikki Joensuu et al. · Journal of Clinical Oncology · 2011 · 81 citations

Surgical Oncology, Immunodeficiencies, Gist Genotypes +19

Long-term follow-up of a phase II randomized trial in advanced gastrointestinal stromal tumor (GIST) patients (pts) treated with imatinib mesylate

Charles D. Blanke, George D. Demetri, Margaret von Mehren et al. · Journal of Clinical Oncology · 2006 · 34 citations

Cancer Management, Gastroenterology, Pathology +18

Reduction of BCR-ABL Transcript Levels at 6, 12, and 18 Months (mo) Correlates with Long-Term Outcomes on Imatinib (IM) at 72 Mo: An Analysis from the International Randomized Study of Interferon versus STI571 (IRIS) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CML-CP)

Timothy P. Hughes, Andreas Hochhaus, Susan Branford et al. · Blood · 2008 · 31 citations